Journal
SCIENTIFIC REPORTS
Volume 11, Issue 1, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41598-021-83968-6
Keywords
-
Categories
Funding
- Swedish Research Council [2017-01737]
- WCMM
- Swedish Cancer Society [2017/581, 2014/780]
- Cancer Research Foundation in Northern Sweden
- Lion's Cancer Research Foundation
- Faculty of Medicine at Umea University
- Umea University
- Region Vasterbotten
- Knut and Alice Wallenberg Foundation
- Swedish Research Council [2017-01737] Funding Source: Swedish Research Council
- Formas [2017-01737] Funding Source: Formas
Ask authors/readers for more resources
This study evaluated protein biomarkers in relation to colorectal cancer risk using prospectively collected plasma samples. The main validation analysis did not show statistically significant proteins, but exploratory subgroup analyses found associations between certain proteins and colon or rectal cancer risk. Adding protein markers to basic risk predictive models modestly improved performance.
Colorectal cancer prognosis is dependent on stage, and measures to improve early detection are urgently needed. Using prospectively collected plasma samples from the population-based Northern Sweden Health and Disease Study, we evaluated protein biomarkers in relation to colorectal cancer risk. Applying a two-tiered approach, we analyzed 160 proteins in matched sequential samples from 58 incident colorectal cancer case-control pairs. Twenty-one proteins selected from both this discovery phase and the literature were then analyzed in a validation set of 450 case-control pairs. Odds ratios were estimated by conditional logistic regression. LASSO regression and ROC analysis were used for multi-marker analyses. In the main validation analysis, no proteins retained statistical significance. However, exploratory subgroup analyses showed associations between FGF-21 and colon cancer risk (multivariable OR per 1 SD: 1.23 95% CI 1.03-1.47) as well as between PPY and rectal cancer risk (multivariable OR per 1 SD: 1.47 95% CI 1.12-1.92). Adding protein markers to basic risk predictive models increased performance modestly. Our results highlight the challenge of developing biomarkers that are effective in the asymptomatic, prediagnostic window of opportunity for early detection of colorectal cancer. Distinguishing between cancer subtypes may improve prediction accuracy. However, single biomarkers or small panels may not be sufficient for effective precision screening.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available